SARASOTA, Florida – July 16, 2013, Mark P. Famiglio, CEO of Cambryn Biologics, a privately held Delaware corporation, announces the launch of its Strategic Advisory Board. “Cambryn is privileged to be working with its Strategic Advisory Board, composed of established international leaders in the pharmaceutical/biotech industry,” said Famiglio. “Ron Gelbman, Carrie Cox, Alan Dunton and Carl Battle have more than 100 combined years of experience as top management within public and private companies. Their expertise continues to ensure Cambryn’s success as it develops human biologic adhesives, hemostats and therapeutic proteins.”
RONALD G. GELBMAN
Mr. Ron Gelbman is a former member of the Executive Committee of Johnson & Johnson. In his last role at Johnson & Johnson, Mr. Gelbman was Worldwide Chairman of the Health Systems and Diagnostics Group and also previously served as Worldwide Chairman of the Pharmaceuticals and Diagnostics Group. His worldwide responsibilities included the pharmaceutical companies Ortho-McNeil Pharmaceutical, Janssen Pharmaceutica, Ortho Biotech and Janssen-Cilag, as well as the Janssen Research Foundation and Pharmaceutical Research Institute. In addition, he was responsible for Health Care Systems, LifeScan, Ortho-Clinical Diagnostics and Therakos. Currently, Mr. Gelbman serves as a Director of Haemonetics Corporation and the SunTrust Southwest Florida Board of Advisors. Among his community activities, Mr. Gelbman is a Trustee at The Out-of-Door College Preparatory School and Rollins College.
Ms. Carrie Cox is Chairman and CEO of Humacyte, Inc., an innovative biomedical engineering company, and recently served as Chairman of Prism Pharmaceuticals, which sold to Baxter Corporation in 2011. Ms. Cox was EVP and President with Global Pharmaceuticals, at Schering-Plough Corporation from 2003 until its merger with Merck & Co., Inc., in November 2009. She was responsible for the company’s global prescription pharmaceutical business which generated approximately $16 billion in annual sales with a five-year CAGR of 22%. Prior to that, she held a similar role as President of Global Prescription Business at Pharmacia Corporation. Ms. Cox has also served as SVP of Global Business Management at Pharmacia & Upjohn, the predecessor company to Pharmacia, and as VP of Women’s Healthcare at Wyeth-Ayerst. Ms. Cox spent her early career at Sandoz pharmaceuticals (now Novartis) in a variety of commercial roles of increasing responsibility. She currently serves on the Boards of Directors of Texas Instruments, Cardinal Health, and Celgene. She has been named six times to FORTUNE Magazine’s list of the “50 Most Powerful Women in Business” and she was named to “Top 10 Women in Biotech” by Fierce Biotech publications in 2012. Her work has been featured in the Harvard Business Review and in the New York Times bestseller, The Profit Zone. She received her B.S. from Massachusetts College of Pharmacy and worked for several years in retail and hospital pharmacy.
ALAN DUNTON, MD
Dr. Dunton is a pharmaceutical/biotechnology product “creator,” entrepreneur, consultant, former Chief Executive Officer and current Director/Chairman of public and private companies with extensive product and company leadership. Dr. Dunton brings over 30 years of experience that covers an entire spectrum of creating start-up biotechnology companies through enhancing in-market products for worldwide pharmaceutical companies. He is currently President and Founder of the consulting firm Danerius LLC and is the former Executive, President, CEO and Chairman for the last 11 years of Panacos Pharmaceuticals Inc., ActivBiotics Inc., Metaphore Pharmaceuticals Inc. and Emisphere Technologies Inc. Dr. Dunton also served as an executive for 18 years for The Janssen Research Foundation, The R.W. Johnson Pharmaceutical Research Institute, Janssen Pharmaceutical/Research Foundation, Syntex Corporation, Ciba-Geigy Corporation, Hoffmann La Roche Inc. and Revlon Health Care Group.
Mr. Battle brings a blend of technology, business, and law from his extensive corporate career. Mr. Battle is currently Senior Vice President and Chief Patent Counsel for GlaxoSmithKline, a UK-based global pharmaceutical company, where he also serves on GlaxoSmithKline’s Scientific Review Board, Technology Investment Board and Legal Management Team. He held previous positions as Senior Vice President at Elan Pharmaceuticals, Vice President of Global Intellectual Property at Pharmacia Corp., Vice President-Patents at Schering-Plough Corp., Senior Director of Patent & Trademark Affairs at Novartis Corp., and Corporate Patent Counsel for Warner-Lambert Co. and Rohm and Haas Co.
Cambryn is a specialty bio-therapeutics company developing human biologic adhesives, hemostats, and therapeutic proteins. Cambryn’s research and development effort is driven by it’s proprietary high yield plasma protein extraction technology to develop next generation products including surgical hemostats.